Acute Kidney Failure Treatment Market Size, Share & Industry Analysis, By Disease Indication (Pre-renal Kidney Failure, Post-renal Kidney Failure, Intrinsic Kidney Failure), By Treatment Type (Medications/ Drug Therapy, Urinary Implants) and Regional Forecast, 2024-2032

In 2015, the U.S Food and Drug Administration granted Expedited Access Pathway status to the wearable artificial kidney (WAK), which can be worn like a belt to perform hemodialysis and will be connected to patient through a catheter. Acute kidney failure refers to a medical condition in which there is sudden damage to the kidney, resulting in inability to filter waste substances from the blood.

Acute kidney failure is the most common complication in diseases such as diabetes, kidney stones, hypertension, prostate cancer, multiple myeloma, liver failure, and many others. The symptoms of acute kidney failure include abdominal pain, nausea, vomiting, dehydration, frequent backache, and others. Moreover, lifestyle habits such as smoking, alcohol consumption, and high dose medications can also lead to acute kidney failure.

Global acute kidney failure treatment market growth is being driven by rapidly increasing prevalence of kidney disorders. Moreover, exponential growth of risk factors which are associated with kidney failures such as hypertension, diabetes, liver failures, and others are also expected to boost the prevalence of kidney failure, which will eventually boost the growth of the global acute kidney failure treatment market during the forecast period.

However, higher cost of acute kidney failure treatment coupled with poor reimbursement policies in emerging nations is expected to restrain the growth of the global acute kidney failure treatment market by 2026.

Key Players Covered

The major companies covered in the global acute kidney failure treatment market report include Fresenius Medical Care, Baxter, B. Braun Melsungen AG, Boston Scientific Corporation, Medtronic, Teleflex Incorporated, Pfizer Inc., Hollister Incorporated, Coloplast Corp., Cure Medical, LLC, Cook, and other players.

Segmentation

As per the current acute kidney failure treatment market trends, drug therapy among the treatment types is projected to hold a major share of the market owing to its higher adoption as it offers comparatively higher benefits than urinary implants.

Key Insights

• Epidemiology of acute kidney failure by key countries


• New product launch by key players


• Reimbursement scenario for key countries


• Key mergers and acquisitions

Regional Analysis

The global acute kidney failure treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In North America, the global acute kidney failure treatment market is likely to grow due to the high prevalence of chronic kidney diseases. According to the Centres of Disease Control and Prevention, in 2017, 30 million people in the United States were estimated to have chronic kidney diseases, which implies a significant growth in the North America acute kidney failure treatment market during the forecast period. In Europe, higher prevalence of risk factors responsible for acute kidney failures such as smoking, hypertension, diabetes, and others are expected to boost the prevalence of acute kidney failure, which will eventually boost the demand for Europe acute kidney failure treatment market by 2026. In Asia Pacific, growing healthcare infrastructure coupled with increasing healthcare infrastructure is anticipated to offer substantial opportunity for the growth of the Asia Pacific acute kidney failure treatment market.

Acute Kidney Failure Treatment Industry Developments

• In October 2018, the association of Mayo clinic and Baxter International Inc. announced the strategic plan to launch Renal Care Center of Excellence (RCCE) in the U.S. with the aim to offer guidance about home hemodialysis, chronic kidney disease management, and in-center hemodialysis to CKD patients.


• In June 2018, Fresenius Medical Care and Humacyte, Inc. agreed upon a strategic partnership to validate the efficacy of HUMACYL, vascular access product for hemodialysis. Moreover, by this partnership, Fresenius Medical Care will get legal rights to commercialize HUMACYL in the global market.